AUD11.25
0.53% today
Australia, Apr 02, 07:10 am CET
ISIN
AU000000CUV3
Symbol
CUV
Sector
Industry

Clinuvel Pharmaceutical Stock price

AUD11.25
-0.98 8.01% 1M
-3.23 22.31% 6M
-0.81 6.72% YTD
-4.30 27.65% 1Y
-6.50 36.60% 3Y
-8.80 43.89% 5Y
+8.06 252.51% 10Y
Australia, Closing price Wed, Apr 02 2025
-0.06 0.53%
ISIN
AU000000CUV3
Symbol
CUV
Sector
Industry

Key metrics

Market capitalization AUD566.19m
Enterprise Value AUD368.69m
P/E (TTM) P/E ratio 14.60
EV/FCF (TTM) EV/FCF 15.70
EV/Sales (TTM) EV/Sales 4.03
P/S ratio (TTM) P/S ratio 6.18
P/B ratio (TTM) P/B ratio 2.61
Dividend yield 0.44%
Last dividend (FY24) AUD0.05
Revenue growth (TTM) Revenue growth 12.74%
Revenue (TTM) Revenue AUD91.57m
EBIT (operating result TTM) EBIT AUD46.51m
Free Cash Flow (TTM) Free Cash Flow AUD23.49m
EPS (TTM) EPS AUD0.77
P/E forward 14.83
P/S forward 5.77
EV/Sales forward 3.76
Show more

Is Clinuvel Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Clinuvel Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Clinuvel Pharmaceutical forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Clinuvel Pharmaceutical forecast:

Buy
100%

Financial data from Clinuvel Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
92 92
13% 13%
100%
- Direct Costs 29 29
7% 7%
31%
63 63
25% 25%
69%
- Selling and Administrative Expenses 11 11
23% 23%
12%
- Research and Development Expense 4.44 4.44
210% 210%
5%
48 48
18% 18%
52%
- Depreciation and Amortization 1.17 1.17
18% 18%
1%
EBIT (Operating Income) EBIT 47 47
18% 18%
51%
Net Profit 39 39
29% 29%
42%

In millions AUD.

Don't miss a Thing! We will send you all news about Clinuvel Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Lachlan Hay
Founded 1999
Website www.clinuvel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today